Compare EU & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | MYGN |
|---|---|---|
| Founded | 2009 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.5M | 429.7M |
| IPO Year | 2011 | 1996 |
| Metric | EU | MYGN |
|---|---|---|
| Price | $2.22 | $4.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | $4.00 | ★ $8.06 |
| AVG Volume (30 Days) | ★ 3.0M | 1.2M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $58,334,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $17.41 | $7.26 |
| Revenue Next Year | $95.45 | $5.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 163.38 | 2.33 |
| 52 Week Low | $1.01 | $3.76 |
| 52 Week High | $4.19 | $11.44 |
| Indicator | EU | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 32.79 | 46.96 |
| Support Level | $1.54 | $4.82 |
| Resistance Level | $2.56 | $5.67 |
| Average True Range (ATR) | 0.19 | 0.37 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 12.00 | 50.62 |
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.